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Abstract
Background: Dysphagia is common in inflammatory myopathies and usually responds to corticosteroids. Severe dysphagia 
requiring feeding by percutaneous endoscopic gastrostomy is associated with significant morbidity and high mortality.
Clinical case: A 56-year old African Black woman initially presented with systemic sclerosis (SSC) - myositis overlap and inter-
stitial lung disease. She responded to high dose corticosteroids and cyclophosphamide followed by azathioprine, with improve-
ment in her lung function and regression of  the skin changes. Six years later she had a myositis flare with severe dysphagia. Her 
myositis improved after high doses of  corticosteroids, azathioprine and two doses of  intravenous immunoglobulin (IVIG). As 
her dysphagia persisted, she was fed via a percutaneous endoscopic gastrostomy (PEG) tube and given a course of  rituximab. 
Her dysphagia gradually resolved and the PEG tube was removed within two months. She received another dose of  rituximab 
six months later and continued low dose prednisone and azathioprine. Her muscle power improved, weight returned to normal 
and she remained well 20 months after hospital discharge.   
Conclusion: Our patient with SSC-myositis overlap and severe dysphagia requiring PEG feeding, improved with high dose 
corticosteroids, azathioprine, two courses of  IVIG and rituximab, and remained in remission 20 months after hospital discharge.
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Introduction
Dysphagia is reported in up to 90% of  patients with sys-
temic sclerosis (SSC) and  20 - 84% of   inflammatory 
myopathies, and may occur at any stage during the course 
of  the disease1. Patients may experience nasal regurgita-
tion, coughing while swallowing and dysphagia for solids 
and liquids2. As a result, percutaneous endoscopic gas-
trostomy (PEG) feeding is required to prevent aspiration 
pneumonia.
The initial treatment of  inflammatory myopathies is high 
dose corticosteroids. Patients’ refractory to corticoste-
roids or who require high doses of  corticosteroids as 
maintenance therapy, may respond to immunosuppres-
sive agents such as methotrexate, azathioprine, cyclo-
phosphamide, cyclosporine or mycophenolate mofetil3.
Intravenous immunoglobulin (IVIG) and rituximab are 
effective in patients with severe, progressive or refractory 
inflammatory myopathy4-8. Patients with refractory oe-
sophageal involvement require PEG feeding and 82.2% 
of  patients may improve with repeated courses of  IVIG4.
 
We report about a patient with SSC - myositis overlap who 
was admitted with a   myositis flare and severe dysphagia. 
She showed a gradual response to feeding via a nasoga-
stric tube followed by PEG tube feeding and intensive 
immunosuppressive therapy. Signed informed consent 
for publication was obtained from the patient and per-
mission was also obtained from the Biomedical Research 
Ethics Committee of  the University of  KwaZulu-Natal.
 
Case report
A 56-year old African Black woman was referred to the 
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rheumatology department at Inkosi Albert Luthuli Cen-
tral Hospital in Durban, South Africa in June 2008. She 
had SSC for one year with involvement of  the face, chest, 
upper and lower limbs, and interstitial lung disease. She 
also had an inflammatory myopathy with weakness of  the 
neck flexors and proximal muscles of  the upper and low-
er limbs. The anti-nuclear antibody was positive in a low 
titre of  1: 40 with a speckled and nucleolar pattern. The 
test for extractable nuclear antigens was negative. The cre-
atine kinase (CK) was 260 units per litre (U/L) (normal 
20 - 180 U/L). Electromyography was consistent with a 
myopathic process and muscle biopsy showed atrophic, 
degenerative and regenerative muscle fibres, mild fibro-
sis and sparse peri-vascular lymphocytes and plasma cells. 
She had a severe restrictive defect on pulmonary function 
tests and high resolution computed tomography (HRCT) 
of  the chest showed intra- and interlobular septal thick-
ening, traction bronchiectasis, basal pleural thickening 
and ground glass opacification consistent with active in-
terstitial lung disease.
 
A diagnosis of  SSC myositis overlap with interstitial lung 
disease was made and she received 2 weekly 500 mg cy-
clophosphamide pulses for twelve weeks followed by aza-
thioprine 100 mg/day. Her initial prednisone dose of  30 
mg/day was gradually tapered to 5 mg/day. A response 
of  the interstitial lung disease was noted with increase in 
the lung volumes on pulmonary function tests. Her mus-
cle power and functional status also improved.
 
She remained well on azathioprine (75-100 mg per day) 
and 5 mg prednisone. There was gradual regression of  
the skin changes on clinical assessment. During the latter 
part of  2012, she had a myositis flare (CK 5085 U/L) 
which responded to a temporary increase in corticoste-
roids. In May 2013 Mycobacterium tuberculosis was identified 
on sputum culture and she was treated with a fixed dose 
combination of  isoniazid, rifampicin, pyrazinamide and 
ethambutol for two months followed by isoniazid and ri-
fampicin for four months.
 
In February 2014, she was admitted with a history of  
progressive increase in muscle weakness and severe dys-
phagia. She had nasal speech and severe muscle weakness 
involving the neck flexors and proximal muscles in the 
upper and lower limbs. Her weight was 43 Kg and the CK 
was raised to 6173 U/L. She was treated with three daily 
pulses of  500 mg methylprednisolone followed by oral 
prednisone 50 mg/day and azathioprine 150 mg/day. She 
was fed via a nasogastric tube and required frequent suc-
tioning as she was unable to swallow her saliva.  A flexible 
naso-endoscopy noted pooling of  saliva in both pyriform 
fossae. As there was no significant improvement, she was 
given a course of  IVIG a week later. During February 
2014, she also had recurrent episodes of  supraventricu-
lar tachycardia which were treated acutely with adenosine 
and then controlled with atenolol.
There was gradual improvement in her peripheral mus-
cle power (CK 2178 U/L) but she still had severe dys-
phagia. She was given a further three day course of  250 
mg methylprednisolone pulses about four weeks after the 
initial dose. Her muscle power improved further with a 
reduction in the CK to 1262 U/L. The dysphagia per-
sisted and a second course of  IVIG was given in March 
2014. In April 2014, the CK had fallen to 438 U/L and 
she developed a Klebsiellsa Pneumoniae urinary tract infec-
tion followed by a severe pneumonia with hypoxia which 
responded to broad spectrum antibiotics. A follow up na-
so-endoscopy was unchanged and therefore a PEG tube 
was inserted and she was started on rituximab 500 mg 
weekly based on her body surface area. She developed 
sepsis around the site of  the PEG tube after three week-
ly doses of  rituximab and therefore the fourth dose was 
omitted.
 
She subsequently showed a gradual and progressive im-
provement in her muscle power and dysphagia. In June 
2014, the CK returned to normal (73 U/L), she was am-
bulant with good muscle power and she was able to swal-
low normally. The PEG tube was removed and she was 
discharged on prednisone 10mg per day and azathioprine 
150 mg/day.
 
Her muscle power improved and weight increased during 
regular out-patient follow-up. In November 2014, the CK 
rose to 470 U/L in the absence of  dysphagia or weak-
ness. In view of  the severity of  her previous illness and 
increased risk of  infection, we chose to give her a lower 
dose of  rituximab and she received two further 500 mg 
doses. The second dose was delayed by two weeks due 
to a urinary tract infection and diarrhea. Her CK fell to 
91 U/L and she continued azathioprine 100 mg/day and 
prednisone 5 mg/day.
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She remained well during 2015 and her CK at the time of  
her last visit in February 2016 was 115 U/L. Her muscle 
power was good and she was eating normally. Her weight 
increased to 61.9 kg. Repeat blood tests showed that the 




Dysphagia is common in patients with inflammatory 
myopathies and its management includes rehabilitation 
measures, corticosteroids and other immunosuppressive 
agents, and rarely surgical measures such as cricopharyn-
geal myotomies and dilatations9. Although the majority 
of  patients with dysphagia respond to corticosteroids, 
case reports and small case series provide evidence for 
the efficacy of  immunosuppressive agents such as aza-
thioprine, methotrexate, cyclosporine, cyclophosphamide 
and MMF for severe dysphagia3. A Cochrane database 
review failed to detect any high quality randomized con-
trolled trials to support the efficacy of  any immunosup-
pressive medication (other than prednisone) in polymy-
ositis (PM) or dermatomyositis (DM)10. Rituximab has 
been shown to be effective for refractory myositis in sep-
arate series of  30 French and 13 Dutch patients6,7. Oddis 
et al showed improvement in 83% of  202 juveniles and 
adults with inflammatory myositis treated with rituximab 
in a randomized study8. However, there are no reports of  
its use for severe dysphagia.
 
Marie et al reported a French multicenter series of  73 
patients with PM and DM who received IVIG for ste-
roid refractory oesophageal involvement4. Nine (12.3%) 
patients required feeding via a PEG or percutaneous 
endoscopic jejunostomy. They found a favorable early 
response in 82.2%, and therefore recommended high 
dose corticosteroids and IVIG as initial therapy for se-
vere dysphagia. Oh et al reported a series of  62 patients 
with inflammatory myopathies and dysphagia and noted 
a high mortality in seven (64%) of  their 11 patients who 
required a PEG9. Das et al reported three patients with 
SSC- myositis overlap with severe dysphagia who required 
PEG feeding for prolonged periods ranging from 5-20 
months11.
 
There are several interesting features in our patient. She 
had diffuse SSC- myositis overlap with regression of  skin 
changes after treatment with cyclophosphamide for her 
interstitial lung disease as noted in 13 (11.1%) of  117 pa-
tients with SSC who were treated with cyclophosphamide 
for interstitial lung disease12.  Although the myositis in 
our patient responded to two courses of  pulse methyl-
prednisolone, high doses of  oral corticosteroids, azathio-
prine and two doses of  IVIG, rituximab was given as she 
had persistent dysphagia and three episodes of  infection 
on high doses of  steroids.  The recovery of  the dysphagia 
with removal of  the PEG within 6 weeks of  rituximab 
therapy permitted discharge of  the patient from hospi-
tal. The contribution of  the rituximab is uncertain as her 
recovery may be due to the delayed effect of  cortico-
steroid and IVIG therapy. The management of  patients 
with severe dysphagia in resource constrained settings is 
challenging. Fortunately, our patient has maintained her 
weight and normal function 20 months after hospital dis-
charge.
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